6/11/2013

Allowing more experts with industry ties to serve on FDA advisory panels could allow more products with dangerous side effects to make it to market, an analysis published in the journal Science says. A 2007 law capped the number of waivers the agency could grant for experts with industry ties, but a 2012 law lifted the cap. Waivers were granted for fewer than 1% of the 608 experts who participated in advisory committees through the first half of 2013, and the agency posts online notice of waivers in advance of meetings, says FDA spokeswoman Stephanie Yao.

Related Summaries